Imunon Stock Forecast for 2023 - 2025 - 2030
Updated on 05/20/2024
Imunon Stock Forecast and Price Target
Imunon's most recent price target of $10.00 for 2024 was provided by renowned analysts over the past few months, with an average prediction of $10.00. If this prediction is correct, Imunon's stock could rise by 614.29 percent from its current trading price. The potential increase for the stock is $10.00 per share, with a possible range of $8.00 to $12.00. If you're interested in IMNN stock, looking at its competitors might also be a good idea.
614.29% Upside
Imunon Fair Value Forecast for 2023 - 2025 - 2030
Imunon's Price has grown in the last year, jumping from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will reach $1.50 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$166.42 | Buy/Sell | $178.42 | 9.66% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$312.47 | Buy/Sell | $303.65 | 2.41% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.72 | Buy/Sell | $87.82 | 18.13% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.57 | Buy/Sell | $299.62 | 25.12% |
Imunon Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Imunon has seen a decline in its Revenue, from $500.00k to $500.00k – a 0.00% decrease. According to the 3 analysts polled, in the next year, Imunon's Revenue will fall by 100.00%, reaching $0.00. For the next seven years, the forecast is for Revenue to grow by 45560.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$77.56 | Buy/Sell | $111.56 | 42.47% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$57.10 | Buy/Sell | $77.05 | 37.48% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$67.00 | Buy/Sell | $34.00 | 71.64% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$104.96 | Buy/Sell | $85.71 | 14.33% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$10.24 | Buy/Sell | $20.42 | 144.14% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.77 | Buy/Sell | $52.00 | 122.04% |
Imunon EBITDA Forecast for 2023 - 2025 - 2030
Imunon's EBITDA has increased by 17.14% In the last three years, going from $-17.74M to $-20.78M. In the following year, 0 experts forecast Imunon's EBITDA will decrease by 4.09%, to $-19.93M. For the next seven years, the forecast is for EBITDA to grow by 0.77%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$9.57 | Buy/Sell | $17.90 | 88.09% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$38.21 | Buy/Sell | $63.29 | 85.82% |
Imunon EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Imunon's EBIT has grown, increasing from $-18.49M to $-21.03M – a growth of 13.74%. The next year looks promising for Imunon, with analysts predicting EBIT of $-25.80M – an increase of 22.68%. Professionals believe that By 2030, Imunon's EBIT will fall to $27.60M– a 231.24% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$14.79 | Buy/Sell | $33.78 | 89.32% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$48.35 | Buy/Sell | $42.58 | 15.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$9.21 | Buy/Sell | $6.00 | 8.58% |
Imunon EPS Price Prediction Forecast for 2023 - 2025 - 2030
Imunon's EPS has grown in the last year, jumping from $-3.96 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will reach $-1.78 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$7.81 | Buy/Sell | $9.94 | 79.26% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.34 | Buy/Sell | $40.00 | 29.59% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.11 | Buy/Sell | $25.00 | 125.02% |
.jpg)